Let's Do the Numbers:
Ahead of the company's earnings announcement, analysts are expecting a positive EPS reading of 96 cents per share and revenues of $1.12 billion. We'll have to wait for Tuesday to see if Forest Laboratories has accomplished the estimated 130% rise in EPS and 105% increase in revenues on a year-over-year basis.Here's how the company's reported EPS has stacked up against analyst estimates in the past:
Quarter | Q4 | Q3 | Q2 | Q1 |
EPS Estimate | $1.08 | 99 cents | 94 cents | 86 cents |
EPS Actual | $1.12 | $1.34 | $1.00 | 95 cents |
Stock Performance:
At last check, shares of Forest Laboratories were trading at $38.61. Shares are up 20.7% year to date.Average Stock Rating:
The average rating by analysts for Forest Laboratories is a Hold. Over the past three months this rating's strength has declined slightly.Competitors:
Wondering how Forest Laboratories compares to rivals in the same sector? Here are a few of the company's peers.- Abbott Laboratories ABT: Hold with a $0.91 recent quarter EPS
- Johnson & Johnson JNJ: Moderate Buy with a $1.35 recent quarter EPS
Forest Laboratories is in the medical-drugs industry, which has experienced price/earnings growth of 2%.
Finally, a description of the main business areas of the company, in case you need a little refresher: Forest Laboratories Inc. and its subsidiaries develop, manufacture and sell prescription drug products.
Take Action:
Now that you've gotten an advanced peak at Forest Laboratories' upcoming earnings numbers, keep an eye out for any surprises in the report and be ready to take action. Also, check back in with us after the announcement for a full recap and a guide to your next steps.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.